Clinical trials: Graft -Versus-host-disease
Chronic Graft-versus-host Disease
MSC for Treatment of cGVHD After Allo-HSCT
The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients with chronic graft-versus-host disease.
- Trial name
- NCT04692376
- Testing
- Mesenchymal stem cells, Glucocorticoids, cyclosporine
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Nanfang Hospital, Southern Medical University
cGvHD
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)
This is a multicenter, single arm, open label phase II clinical study in China. This study will evaluate the efficacy and safety of ABSK021 (Pimicotinib) in the treatment of patients with cGvHD who failed first-line therapy.
- Trial name
- NCT06186804
- Testing
- ABSK021
- Where
- 14 sites in China
- Volunteers
- 64 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Acute Graft Versus Host Disease
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
The study was an open-label, single-arm, Phase I/II multi-center study to investigate the PK, activity and safety of ruxolitinib added to the patient's immunosuppressive regimen in infants, children, and adolescents ages ≥28 days…
- Trial name
- NCT03491215
- Testing
- Ruxolitinib
- Where
- 19 sites in Belgium, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Graft vs Host Disease
Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease
Chronic Graft-versus-Host Disease (cGVHD) is an important cause of morbidity and mortality in patients undergoing allogeneic bone marrow transplantation.
- Trial name
- cGVHD (NCT00632658)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Acute Myeloid Leukemia
Samples From Leukemia Patients and Their Donors to Identify Specific Antigens
The purpose of this project is to develop a process to identify highly personalized antigens that are uniquely expressed by the patient's own leukemia cells that can be used for cellular immune therapy.
- Trial name
- NCT02667093
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- PersImmune, Inc
Partial-thickness Burn, Ulcer
NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing
This study is designed to assess the efficacy and economics of two NPWT (negative pressure wound therapy) branded devices of wound healing outcomes.
- Trial name
- NCT02519621
- Testing
- NPWT PRO without irrigation, NPWT PRO with irrigation, KCI Ulta
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Larry Lavery
Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
This open-label, Phase I study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of GDC-0853 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
- Trial name
- NCT01991184
- Testing
- GDC-0853
- Where
- 10 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Dyslipidemia
Short Message Service (SMS) Impact on Patient Compliance Receiving Long Term Lipid Lowering Therapy With Statins
The objective of the study is to determine whether short text massages could be used successfully as a compliance aid and improve clinical outcomes in long term lipid lowering therapy.
- Trial name
- NCT00829348
- Testing
- No intervention, Short Message Service (SMS)
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Hillel Yaffe Medical Center
Graft Versus Host Disease, Cancer
Extracorporeal Photopheresis for Acute Graft Versus Host Disease
The purpose of this research study is to evaluate the safety and feasibility of extracorporeal photopheresis (ECP) in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in children.
- Conditions
- Graft Versus Host Disease, Cancer, Stem Cell Transplantation
- Trial name
- NCT00179855
- Testing
- Extracorporeal Photopheresis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Graft Versus Host Disease
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft…
- Trial name
- NCT04886726
- Testing
- uhCG/EGF
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Henry Ford Health System
Anemia, Kidney Disease, Chronic
A Retrospective Observational Study of Hemoglobin Levels in Patients With Renal Anemia Treated With Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)
This retrospective observational study will evaluate the hemoglobin levels in patients with renal anemia over 6 months treatment with Mircera (methoxy polyethylene glycol-epoetin beta).
- Trial name
- NCT01379963
- Where
- 17 sites in Greece
- Volunteers
- 780 people
- Sponsor
- Hoffmann-La Roche
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00253552
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Hepatitis C Virus Infection
Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
The primary objectives of the study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (Vosevi®; SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks and of…
- Trial name
- POLARIS-4 (NCT02639247)
- Testing
- SOF/VEL/VOX, SOF/VEL
- Where
- 78 sites in United States, Australia and 6 more
- Volunteers
- 333 people
- Sponsor
- Gilead Sciences
Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
The purpose of the study is to determine if participants who receive the GVHD prophylaxis medication pentostatin will have less severe hepatic toxicities than those receiving MTX.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Hodgkin's Disease
- Trial name
- NCT01188798
- Testing
- Methotrexate, Pentostatin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia
HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk
Patients with de novo AML enrolled in the study. Patient who has a HLA-identical donor is assigned to receive NST therapy with GVHD prophylaxis and who has no HLA-identical donor is assigned to receive MST therapy without GVHD…
- Trial name
- NCT02461121
- Testing
- HLA mismatched stem cell, HLA matched stem cell, cyclosporine A
- Where
- China
- Volunteers
- 156 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Graft-Versus-Host Disease
Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT
Ocular Graft Versus Host Disease (OGVHD) is a serious potential complication of allogeneic bone marrow transplants. The usual treatment is topical cyclosporine but when the treatment is initiated the damage to the lacrimal glands…
- Trial name
- HSCT (NCT02144025)
- Testing
- Cyclosporine
- Where
- Mexico
- Volunteers
- 21 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Graft Versus Host Disease, Ocular Surface Disease
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of ocular Graft Verses Host Disease (oGVHD).
- Conditions
- Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease
- Trial name
- oGVHD (NCT03591874)
- Testing
- Brimonidine Tartrate
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ocugen
Graft Vs Host Disease, Haematological Malignancy
oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort
Allogeneic Haematopoietic stem cell transplantation (HSCT) is an effective treatment for all array of blood or blood-producing organ disorders.
- Conditions
- Graft Vs Host Disease, Haematological Malignancy, Cancer
- Trial name
- NCT05170347
- Where
- Hong Kong
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Chronic Graft-versus-host-disease
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
This research study is evaluating a combination of a therapy called Extra-corporeal Photopheresis (ECP) with a drug called Interleukin-2 (IL-2) as a possible treatment for chronic graft-versus-host-disease (GVHD) following…
- Trial name
- NCT02340676
- Testing
- Extracorporeal Photopheresis (ECP), Interleukin-2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.